CHEN Yunhui,XIA Jun,LIU Xinglong,et al.Protective Effect of Danggui Shaoyaosan-contained Serum on Aβ1-40-injured PC12 Cells via Regulating UPP and Its Mechanism[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(24):17-25.
CHEN Yunhui,XIA Jun,LIU Xinglong,et al.Protective Effect of Danggui Shaoyaosan-contained Serum on Aβ1-40-injured PC12 Cells via Regulating UPP and Its Mechanism[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(24):17-25. DOI: 10.13422/j.cnki.syfjx.20211207.
Protective Effect of Danggui Shaoyaosan-contained Serum on Aβ1-40-injured PC12 Cells via Regulating UPP and Its Mechanism
To investigate the protective effect of Danggui Shaoyaosan (DSS)-contained serum on
β
-amyloid (A
β
)
1-40
-injured rat adrenal pheochromocytoma PC12 cells and its mechanism in regulating ubiquitin-proteasome pathway (UPP).
Method
2
A
β
1-40
was used to intervene PC12 cells to prepare the cell models of Alzheimer's disease (AD), and the experiment was divided into the blank, model, and DSS-contained serum high, medium, and low-dose groups (10%, 5%, and 2.5%). Cell viability and apoptosis were detected using cell counting kit-8 (CCK-8) method and flow cytometry, respectively. The content of A
β
and p-Tau protein was determined by enzyme-linked immunosorbent assay (ELISA). The ubiquitin (Ub), ubiquitin ligase E3 (E3), 26S proteasome, ubiquitin carboxyl terminal hydrolase1 (UCHL1), and UCHL3 protein expressions of UPP were displayed using immunofluorescence cytochemistry (ICC), and the mRNA and protein expression levels of Ub, E3-parkin, 26S, UCHL1, and UCHL3 were determined by real-time fluorescent quantitative polymerase chain reaction (Real-time PCR) and Western blot, respectively.
Result
2
The data of the CCK8 experiment verified that 5 μmol·L
-1
and 48 hours were the optimal conditions for modeling A
β
1-40
-injured PC12 cells. As compared with the blank group, the cell viability rate in the model group decreased (
P
<
0.05) with an increased apoptosis rate (
P
<
0.05), the content of A
β
and p
-
Tau contents was elevated (
P
<
0.05), the mRNA and protein expression levels of Ub increased, and the mRNA and protein expression levels of 26S, E3, and UCHL1+3 decreased (
P
<
0.05). As compared with the model group, the cell viability rate in the DSS-contained medium-dose group increased (
P
<
0.05), whereas the apoptosis rate in each DSS-contained group decreased (
P
<
0.05). The content of A
β
in each DDS-contained group decreased (
P
<
0.05), and the content of p-Tau in the DDS-contained high and medium-dose groups decreased (
P
<
0.05). The mRNA expression level of Ub decreased, and that of 26S increased in each DDS-contained group (
P
<
0.05). The mRNA expression level of UCHL1 in the DDS-contained medium-dose group increased (
P
<
0.05), and the mRNA expression levels of E3 and UCHL 3 in the DDS-contained high and medium-dose groups increased (
P
<
0.05). The protein expression level of Ub in each DDS-contained group decreased, and the protein expression levels of 26S, E3, and UCHL1+3 in the DDS high and medium-dose groups increased. The DSS-contained serum medium-dose group exerted the optimal effect.
Conclusion
2
DSS-contained serum can increase cell viability rate, reduce cell apoptosis rate, eliminate A
β
and p-Tau protein deposits, and exert protective effects on A
β
1-40
-injured PC12 cells. Its mechanism may involve UPP via decreasing the expression of Ub and increasing that of 26S, E3, UCHL1, and UCHL3.
关键词
Keywords
references
OBOUDIYAT C , GLAZER H , SEIFAN A , et al . Alzheimer's disease [J]. Semin Neurol , 2013 , 33 ( 4 ): 313 - 329 .
TIWARI S , ATLURI V , KAUSHIK A , et al . Alzheimer's disease: Pathogenesis, diagnostics, and therapeutics [J]. Int J Nanomedicine , 2019 , 14 : 5541 - 5554 .
CIECHANOVER A , KWON Y T . Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies [J]. Exp Mol Med , 2015 , 47 ( 3 ): e147 .
GONG B , RADULOVIC M , FIGUEIREDO-PEREIRA M E , et al . The ubiquitin-proteasome system: Potential therapeutic targets for Alzheimer's disease and spinal cord injury [J]. Front Mol Neurosci , 2016 , 9 : 4 .
TRAMUTOLA A , DI DOMENICO F , BARONE E , et al . It is all about (U)biquitin: Role of altered ubiquitin-proteasome system and UCHL1 in Alzheimer disease [J]. Oxid Med Cell Longev , 2016 , 2016 : 2756068 .
CIECHANOVER A , KWON Y T . Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies [J]. Exp Mol Med , 2015 , 47 ( 3 ): e147 .
KIM Y , CHO S H . Danggui-Shaoyao-San for dementia: A PRISMA-compliant systematic review and meta-analysis [J]. Medicine (Baltimore) , 2020 , 99 ( 4 ): e18507 .
ASHRAF G M , GREIG N H , KHAN T A , et al . Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus [J]. CNS Neurol Disord Drug Targets , 2014 , 13 ( 7 ): 1280 - 1293 .
JOHNSTON H E , SAMANT R S . Alternative systems for misfolded protein clearance: Life beyond the proteasome [J]. FEBS J , 2021 , 288 ( 15 ): 4464 - 4487 .
NANDI D , TAHILIANI P , KUMAR A , et al . The ubiquitin-proteasome system [J]. J Biosci , 2006 , 31 ( 1 ): 137 - 155 .
SCHMIDT M F , GAN Z Y , KOMANDER D , et al . Ubiquitin signalling in neurodegeneration: Mechanisms and therapeutic opportunities [J]. Cell Death Differ , 2021 , 28 ( 2 ): 570 - 590 .
AGOSTON V , CSERMELY P , PONGOR S . Multiple weak hits confuse complex systems: A transcriptional regulatory network as an example [J]. Phys Rev E Stat Nonlin Soft Matter Phys , 2005 , 71 ( 5 Pt 1 ): 051909 .
CHENG B , GONG H , XIAO H , et al . Inhibiting toxic aggregation of amyloidogenic proteins: A therapeutic strategy for protein misfolding diseases [J]. Biochim Biophys Acta , 2013 , 1830 ( 10 ): 4860 - 4871 .
PERRY G , FRIEDMAN R , SHAW G , et al . Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains [J]. Proc Natl Acad Sci U S A , 1987 , 84 ( 9 ): 3033 - 3036 .
HARRIS L D , JASEM S , LICCHESI J . The ubiquitin system in Alzheimer's disease [J]. Adv Exp Med Biol , 2020 , 1233 : 195 - 221 .
AL MAMUN A , UDDIN M S , KABIR M T , et al . Exploring the promise of targeting ubiquitin-proteasome system to combat Alzheimer's disease [J]. Neurotox Res , 2020 , 38 ( 1 ): 8 - 17 .
GADHAVE K , BOLSHETTE N , AHIRE A , et al . The ubiquitin proteasomal system: A potential target for the management of Alzheimer's disease [J]. J Cell Mol Med , 2016 , 20 ( 7 ): 1392 - 1407 .
GRAHAM S H , LIU H . Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia [J]. Ageing Res Rev , 2017 , 34 : 30 - 38 .
ZHANG M , CAI F , ZHANG S , et al . Overexpression of ubiquitin carboxyl-terminal hydrolase L1(UCHL1)delays Alzheimer's progression in vivo [J]. Scientific Reports , 2014 , 4 : 7298 .
Danggui Shaoyaosan Inhibits Neuroinflammation in AD Rats by Regulating NLRP3/Caspase-1 Pathway
Prevention and Treatment of Alzheimer's Disease by Traditional Chinese Medicine via Regulating ROS: A Review
Mechanism of Linggui Zhugantang in Promoting Astrocyte Endocytosis and Degradation of Amyloid β
Danggui Shaoyaosan Regulates Autophagy via AMPK/mTOR/ULK1 Signaling Pathway in Rat Model of Metabolism-associated Fatty Liver Disease
Effect of Danggui Shaoyaosan on Mitochondrial Homeostasis and AMPK/SIRT1/PGC-1α Signaling Pathway in Rats Model of Alzheimer's Disease
Related Author
Zhen-yan SONG
Xiao-fang XIA
Yu-ke WANG
Yu-shan ZHENG
Pei-ying CHEN
De-yong LUO
Chun-xiang HE
Wen-jing YU
Related Institution
Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, Hunan University of Chinese Medicine
Gansu Key Laboratory of Chinese Medicine Mining and Innovation Transformation,Key Laboratory of Dunhuang Medicine and Transformation,Ministry of Education,Gansu University of Chinese Medicine
Gansu University of Chinese Medicine
College of Traditional Chinese Medicine, College of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine